RECOMBINA participates in a study for evaluating a novel live attenuated vaccine against Salmonella

RECOMBINA participates in a study for evaluating a novel live attenuated vaccine against Salmonella

Wednesday October 12th, 2016

In collaboration with researchers from Navarrabiomed and the Center for Applied Medical Research CIMA of the Universidad de Navarra, RECOMBINA has participated in a study aimed at the evaluation and characterization of the immune response raised against a modified strain of Salmonella Enteritidis. This particular strain lacks the whole machinery for synthesizing the secondary messenger c-di-GMP and is additionally defective in the sigma regulator RpoS. Results of such a study, recently published in the PLOS ONE journal, show that the modified strain is totally avirulent, and thus safe, and it is capable of inducing a protective immune response based on the induction of opsonizing antibodies and the production of high levels of relevant cytokines like IFN-γ, TNF-α, IL-2, IL-17 e IL-10. In view of these results, this strain of Salmonella Enteritis is considered as a promising candidate for vaccination against salmonellosis in farm animals, as well as an attractive bacterial vector for heterologous expression of viral and tumor antigens.

Latasa C, Echeverz M, García B, Gil C, García-Ona E, Burgui S, et al. (2016) Evaluation of a Salmonella Strain Lacking the Secondary Messenger C-di-GMP and RpoS as a Live Oral Vaccine. PLoS ONE 11(8): e0161216. doi:10.1371/journal.pone.0161216 | READ MORE »